Published in Blood Weekly, June 8th, 2000
Most notably, 76% of patients achieved a complete remission, with no sign of cancer. In addition, 84% of patients with evidence of lymphoma at the molecular level at the start of the trial achieved molecular remission for as long as three years with the treatment. Molecular remissions were determined by polymerase chain reaction (PCR) technology.
These promising results, from the first completed study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.